Metformin: Comprehensive NHS-Aligned Information

Metformin is a biguanide drug that has been the cornerstone of type 2 diabetes treatment since its introduction to the UK market in 1958.

It is one of the most widely prescribed medicines in the world, with over 20 million prescriptions dispensed annually in England alone.

Metformin works through three main mechanisms:

1. Reducing hepatic glucose output

The liver normally releases glucose between meals through gluconeogenesis (making new glucose) and glycogenolysis (breaking down stored glycogen).

Metformin suppresses both processes, reducing the amount of glucose entering the bloodstream. This is its primary mechanism and accounts for the majority of its glucose-lowering effect.

2. Improving insulin sensitivity

Metformin enhances the ability of muscle cells to take up glucose in response to insulin.

This means the body can manage blood glucose more effectively with the insulin it already produces, without needing to secrete more.

3. Slowing intestinal glucose absorption

Metformin has a modest effect on reducing glucose uptake from the gut, contributing to its overall glucose-lowering action.

Because metformin does not stimulate insulin secretion, it very rarely causes hypoglycaemia when used alone.

This is a significant safety advantage over other diabetes drugs such as sulphonylureas and insulin.

NICE guideline NG28 recommends metformin as the first drug to try for all adults newly diagnosed with type 2 diabetes, unless there is a specific contraindication.

Metformin is available in the UK in several formulations, all of which are prescribed generically on the NHS at minimal cost.

Immediate-release (standard) tablets

• Available strengths: 500 mg and 850 mg
• Starting dose: 500 mg once daily with food (usually with the evening meal)
• Titration: increase by 500 mg every 1 to 2 weeks as tolerated
• Usual maintenance dose: 500 mg to 850 mg two to three times daily
• Maximum dose: 2,000 mg per day (some guidelines permit 2,550 mg in divided doses)

Modified-release (MR/slow-release) tablets

• Available strengths: 500 mg and 1,000 mg
• Starting dose: 500 mg once daily with the evening meal
• Titration: increase by 500 mg every 1 to 2 weeks
• Usual maintenance dose: 1,000 mg to 2,000 mg once daily
• Maximum dose: 2,000 mg per day

Modified-release tablets are taken once daily, usually with the evening meal, and release the drug slowly over several hours.

This reduces peak concentrations in the gut and significantly improves GI tolerability.

The BNF notes that MR formulations are appropriate first-line if GI side effects are anticipated or if a patient has previously not tolerated standard-release tablets.

Oral solution

A 500 mg/5 mL liquid formulation is available for patients who cannot swallow tablets. It is more expensive than tablets and is typically reserved for specific clinical needs.

Cost

Metformin is extremely cost-effective. A month's supply of standard 500 mg tablets costs the NHS approximately 90 pence, making it one of the cheapest chronic disease treatments available.

Regular monitoring ensures metformin continues to work safely and effectively. The NHS diabetes annual review covers most of these checks, but some may be needed more frequently.

HbA1c (glycated haemoglobin)

This blood test reflects your average blood glucose over the preceding 2 to 3 months.

NICE recommends checking HbA1c every 3 to 6 months when treatment is being adjusted, then at least every 6 months once stable.

The target for most type 2 diabetes patients on metformin alone is 48 mmol/mol (6.5%) or an individualised target agreed with your diabetes team.

Kidney function (eGFR and creatinine)

Renal function should be checked before starting metformin and at least annually thereafter. If eGFR is between 45 and 59, check every 6 months.

If between 30 and 44, check every 3 months and reduce the dose. Stop metformin if eGFR falls below 30.

Vitamin B12

Patients on metformin for more than 3 to 4 years should have B12 levels checked, particularly if they develop symptoms suggestive of deficiency (fatigue, paraesthesia, macrocytosis).

NICE guideline NG28 specifically highlights the importance of monitoring B12 in long-term metformin users.

Full blood count

An annual FBC can detect macrocytic anaemia caused by B12 or folate deficiency. An unexplained rise in mean cell volume (MCV) should prompt B12 and folate measurement.

Blood pressure, lipids and weight

These are part of the standard diabetes annual review and help assess overall cardiovascular risk. Metformin has a neutral to slightly beneficial effect on all three parameters.

Foot checks, eye screening and urine albumin

These are diabetes-specific screening tests rather than metformin-specific, but they are essential components of your annual review.

In the UK, metformin is a prescription-only medicine. It cannot be bought over the counter. Here is how the prescribing process typically works.

Diagnosis of type 2 diabetes

Metformin is usually initiated after a formal diagnosis of type 2 diabetes, confirmed by an HbA1c of 48 mmol/mol (6.5%) or above on two separate occasions, or a single result above 48 with symptoms.

Your GP will typically make the diagnosis and start treatment.

Initial consultation

Your GP or practice nurse will:

• Confirm the diagnosis with blood tests
• Check your kidney function (eGFR), liver function and full blood count
• Review your medical history for contraindications
• Discuss lifestyle changes (diet, exercise, weight management)
• Start metformin at 500 mg once daily and arrange a follow-up in 2 to 4 weeks

Ongoing prescriptions

Once established on metformin, you will receive repeat prescriptions.

Most GP practices issue these electronically, allowing you to order your medication through the NHS App, an online patient portal or by contacting the surgery directly.

Prescription costs

Patients with diabetes are eligible for a free medical exemption certificate (medex), which entitles you to all NHS prescriptions free of charge, not just diabetes medications.

Your GP surgery or diabetes nurse can help you apply.

Diabetes education

The NHS offers free structured education programmes such as DESMOND (Diabetes Education and Self-Management for Ongoing and Newly Diagnosed) and X-PERT.

These programmes cover medication, diet, exercise, blood glucose monitoring and complication prevention. Ask your GP or diabetes nurse for a referral.

Metformin is almost always the first medicine started for type 2 diabetes, but as the condition progresses, additional treatments may be needed to maintain glucose control.

NICE guideline NG28 provides a clear treatment pathway.

Step 1: Metformin alone

If HbA1c remains above target after 3 to 6 months of metformin at maximum tolerated dose plus lifestyle changes, a second drug is added.

Step 2: Metformin plus a second agent

The main options include:

• Sulphonylureas (gliclazide): stimulate insulin secretion; risk of hypoglycaemia and weight gain
• SGLT2 inhibitors (dapagliflozin, empagliflozin): reduce glucose reabsorption in the kidneys; associated with weight loss and cardiovascular/renal benefits
• DPP-4 inhibitors (sitagliptin, linagliptin): enhance incretin hormones; weight-neutral with a good tolerability profile
• GLP-1 receptor agonists (semaglutide, liraglutide): injected therapies that produce significant weight loss and cardiovascular benefit; increasingly used earlier in treatment

Step 3: Triple therapy or insulin

If dual therapy is insufficient, a third oral agent, a GLP-1 agonist or basal insulin may be added to metformin.

Metformin is usually continued alongside insulin because it reduces the insulin dose required and limits insulin-associated weight gain.

Cardiovascular and renal protection

NICE now recommends SGLT2 inhibitors for patients with established cardiovascular disease or chronic kidney disease regardless of HbA1c, reflecting the significant evidence of benefit from trials such as EMPA-REG OUTCOME and DAPA-CKD.

Metformin remains the foundation of treatment at every step. It is rarely stopped unless a genuine contraindication develops.

Metformin's benefits extend beyond glucose lowering, which is one reason it has remained the preferred first-line therapy for over 60 years despite the arrival of many newer drugs.

Cardiovascular protection

The UKPDS trial demonstrated that metformin reduced all-cause mortality by 36% and diabetes-related death by 42% in overweight patients with type 2 diabetes compared with diet alone.

This cardiovascular benefit was independent of glucose control and has not been matched by any other oral diabetes drug in a randomised trial.

Cancer risk reduction

Observational studies consistently associate metformin use with a 10 to 30% lower incidence of several cancers, including colorectal, breast, liver and pancreatic cancer.

The proposed mechanism involves metformin's activation of AMP-activated protein kinase (AMPK), which suppresses cell growth and proliferation.

Randomised trials are ongoing, but the signal is strong enough to be considered a potential bonus of treatment.

Anti-ageing research

The TAME (Targeting Aging with Metformin) trial is investigating whether metformin can delay age-related diseases in non-diabetic individuals.

While results are not yet available, the trial reflects the scientific community's growing interest in metformin's pleiotropic effects.

Cost-effectiveness

At approximately 1 penny per tablet, metformin is extraordinarily cost-effective.

It would need to be only marginally beneficial to justify its use from a health-economic perspective, and in fact it delivers substantial clinical value.

Safety track record

Over 60 years of real-world use involving hundreds of millions of patients provides a level of safety data that no newer drug can match.

Serious adverse events are rare and well-characterised, making metformin one of the most thoroughly understood medicines in clinical practice.